Calypte Biomedical Announces the Appointment of Martin Landau to Its Board of Directors.

Business Editors & Health/Medical Writers

ALAMEDA, Calif.--(BW HealthWire)--May 31, 2002

To Play Active Role in Promoting Increased Public

Awareness of Proprietary HIV-1 Urine-Screening Test

Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced the appointment of Academy-Award winner Martin Landau to the Company's Board of Directors.

"Our number one objective is to increase the public's awareness of Calypte's proprietary HIV-1 urine screening tests, and we expect Martin Landau to play an active role in this process," said Anthony Cataldo, Executive Chairman at Calypte.

"Martin is not only respected among his peers as one of the finest actors of his generation, but he is also known for his involvement in humanitarian causes and has been at the forefront in the fight against AIDS. His willingness to accept the invitation to join our board adds tremendous credibility and stature to our organization," Mr. Cataldo added.

Martin Landau received an Academy Award for his 1994 portrayal of Bela Lugosi in Tim Burton's "Ed Wood" and received two consecutive Oscar nominations for Francis Ford Coppola's "Tucker: The Man and His Dream" and for Woody Allen's "Crimes and Misdemeanors." Mr. Landau has also appeared in many television productions, most notably the adventure/espionage series "Mission: Impossible."

"I believe in Calypte's mission to provide reliable, safe, and inexpensive alternative products for the detection of HIV throughout the world and intend to play an active role in spreading the word about this company's humanitarian products," Landau stated.

About Calypte Biomedical:

Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-based tests, our testing algorithms are non-invasive, easier to use, less expensive and have significantly less risk than blood-based testing, and they have 99.7% sensitivity in subjects previously identified as HIV-1 infected and 100% specificity in subjects at low risk when combined with the urine-based Western Blot supplemental test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2001 and its subsequent filings with the SEC.